Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Leonardo Passos Chaves
Observed names:
L Chaves,
L. Chaves,
Leonardo Chaves
Institution:
Bausch Health (United States)
Observed institutions:
AbbVie (United States),
Bausch Health (United States),
Bausch Health (Germany),
Eisai (United States),
Astellas Pharma (United States),
Brazilian Association of Psychiatry,
Abbott (Brazil)
show all 7
ORCID:
0000-0002-1881-0760
Observed ORCID:
0000-0002-1881-0760
OpenAlex ID:
A5011051485
Nicotine use in patients with schizophrenia evaluated by the Fagerström Tolerance Questionnaire: a descriptive analysis from a Brazilian sample
2008
·
Leonardo Chaves
, Itiro Shirakawa
·
Brazilian Journal of Psychiatry
·
21
PDF
Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn’s disease in Argentina, Brazil, Colombia, and Mexico
2016
·
Namita Tundia
, Paulo Gustavo Kotze
, et al.
·
Journal of Medical Economics
·
15
PDF
The cost impact of disease progression to metastatic castration-sensitive prostate cancer
2022
·
Quoc-Dien Trinh
, Leonardo Passos Chaves
, et al.
·
Journal of Managed Care & Specialty Pharmacy
·
9
PDF
Treatment patterns, healthcare resource utilization and costs of HER2-negative gastric/gastroesophageal junction cancer
2023
·
Rupali Fuldeore
, Leonardo Passos Chaves
, et al.
·
Future Oncology
·
4
PDF
Ee120 Excess Healthcare Costs of Overt Hepatic Encephalopathy (ohe) Relative to Non-ohe Cirrhosis in the United States
2026
·
Arun B. Jesudian
, Debbie Goldschmidt
, et al.
·
Value in Health
Hsd106 Pathways of Care and Access to Rifaximin Post-discharge in Medicare-insured Patients With Overt Hepatic Encephalopathy
2026
·
Arun B. Jesudian
, Patrick Gagnon-Sanschagrin
, et al.
·
Value in Health
Ee229 Caregiver Burden and Socioeconomic Impact of He and Ohe Among Individuals Caring for Patients With Cirrhosis
2026
·
Arun B. Jesudian
, Debbie Goldschmidt
, et al.
·
Value in Health
Ee332 Incremental Healthcare Costs Associated With Decompensation Events Among Patients With Cirrhosis in the United States
2026
·
Arun B. Jesudian
, Arthur Voegel
, et al.
·
Value in Health
Sa2018 EXCESS ECONOMIC BURDEN OF OVERT HEPATIC ENCEPHALOPATHY (OHE) RELATIVE TO NON-OHE CIRRHOSIS IN THE UNITED STATES: A SOCIETAL PERSPECTIVE
2026
·
Arun Jesudian
, Debbie Goldschmidt
, et al.
·
Gastroenterology
Mo2120 EXPERT CONSENSUS ON RISK FACTORS FOR A FIRST EPISODE OF OVERT HEPATIC ENCEPHALOPATHY IN CIRRHOSIS: A DELPHI STUDY
2026
·
Arun Jesudian
, Aditi Shah
, et al.
·
Gastrointestinal Endoscopy
Mo2120 EXPERT CONSENSUS ON RISK FACTORS FOR A FIRST EPISODE OF OVERT HEPATIC ENCEPHALOPATHY IN CIRRHOSIS: A DELPHI STUDY
2026
·
Arun Jesudian
, Aditi Shah
, et al.
·
Gastroenterology
Sa2018 EXCESS ECONOMIC BURDEN OF OVERT HEPATIC ENCEPHALOPATHY (OHE) RELATIVE TO NON-OHE CIRRHOSIS IN THE UNITED STATES: A SOCIETAL PERSPECTIVE
2026
·
Arun Jesudian
, Debbie Goldschmidt
, et al.
·
Gastrointestinal Endoscopy
Quantifying treatment value under IRA: a case study of rifaximin for the treatment of overt hepatic encephalopathy using QALY and non-QALY measures
2025
·
Shanshan Wang
, Leonardo Passos Chaves
, et al.
·
Journal of Medical Economics
PDF
RWD157 K2GC: Real-world Treatments and Outcomes Amongst Patients With Resectable Gastric (GC) and Gastroesophageal Junction Cancer (GEJC) in the United States (US)
2025
·
Leonardo Passos Chaves
, Michael Baglio
, et al.
·
Value in Health
Prevalence of historical medical conditions or comorbidities with potential role in clinical decision making related to suitability of immuno-oncologic plus IV antiangiogenic therapy in newly diagnosed first-line unresectable hepatocellular carcinoma in the United States.
2023
·
Tammy Schuler
, Leonardo Passos Chaves
, et al.
·
Journal of Clinical Oncology
Pgi5 Long Term Economic Value of Tight Control With Adalimumab-based Treatment in Crohn's Disease: the Brazilian Public Healthcare System Perspective
2019
·
R. Saad-Hossne
, R. dos Santos
, et al.
·
Value in Health
PDF
Psy81 - Direct Costs Associated With the Treatment of Chronic Lymphocytic Leukemia (cll) Relapsed or Refractory in Argentina
2018
·
M.L. Godar
, L. Chaves
, et al.
·
Value in Health
Cost-Minimization of Adalimumab and Infliximab In Patients With Moderate To Severe Ulcerative Colitis Refractory To Conventional Therapy
2017
·
K Jones
, R Rivera Hurtado
, et al.
·
Value in Health
P449 Patient support program for adalimumab-treated patients with Crohn's disease in Brazil: impact on patients' adherence and persistence
2017
·
V. Teich
, R. Arinelli
, et al.
·
Journal of Crohn s and Colitis
Economic Impact of Expanded Use of Biologic Therapy for Crohn’s Disease In Latin American Countries
2015
·
PG Kotze
, N Tundia
, et al.
·
Value in Health
PDF
Projected Economic Impact of Increased Use of Biologic Treatments For Rheumatoid Arthritis In Argentina, Colombia, And Mexico Over 10 Years
2015
·
J Rojas Serrano
, MM de Abreu
, et al.
·
Value in Health
PMS13 Economic Model of Workplace Impacts of anti-Tnf therapy for Rheumatoid Arthritis in Brazil
2011
·
V. Teich
, L. Chaves
, et al.
·
Value in Health
Show more works
View as search
Works count:
22
Citation count:
49
H-index:
4
I10-index:
2
Year
Topic
Type